GPCM
OBIO icon

Granite Point Capital Management’s Orchestra BioMed OBIO Stock Holding History

Granite Point Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-48,000
Closed -$539K – 183
2021
Q1 		$539K Hold
48,000
– – 0.02% 162
2020
Q4 		$615K Sell
48,000
-52,000
-52% -$593K 0.03% 136
2020
Q3 		$1.1M Buy
+100,000
New +$1.12M 0.06% 118

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Granite Point Capital Management's OBIO Position: Q2 2021 in Review

Granite Point Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2021, closing a stake of 48,000 shares — an estimated $539K sold.

Granite Point Capital Management first reported a position in OBIO in Q3 2020 and held it in 3 quarters. The position peaked at $1.1M in Q3 2020. 50 funds tracked by Wall St. Rank hold OBIO as of Q2 2021.

  • Granite Point Capital Management reported no remaining Orchestra BioMed position as of Q2 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 48,000 Orchestra BioMed shares in Q2 2021, an estimated $539K.
  • Granite Point Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 3 quarters.
  • Granite Point Capital Management's Orchestra BioMed position peaked at $1.1M in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2021.

Based on Granite Point Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.